<table id="ID170" width="99%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3 Incidence of Primary Endpoint Events</caption>
<col width="18%"></col>
<col width="16%"></col>
<col width="16%"></col>
<col width="16%"></col>
<col width="17%"></col>
<col width="16%"></col>
<tbody>
<tr>
<td align="left" colspan="1" valign="top">
<br/>
</td>
<td align="center" colspan="2" valign="top">Incidence<br/>
</td>
<td align="center" colspan="1" valign="top">Risk Reduction<br/>
</td>
<td align="center" colspan="1" valign="top">95% C.I.<br/>
<br/>
</td>
<td align="center" colspan="1" valign="top">p-Value<br/>
<br/>
</td>
</tr>
<tr>
<td align="left" valign="top">
<br/>
</td>
<td align="center" valign="top">Losartan<br/>
</td>
<td align="center" valign="top">Placebo<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" valign="top">Primary Composite Endpoint <br/>
</td>
<td align="center" valign="top">43.5%<br/>
<br/>
</td>
<td align="center" valign="top">47.1%<br/>
<br/>
</td>
<td align="center" valign="top">16.1%<br/>
<br/>
</td>
<td align="center" valign="top">2.3% to<br/>27.9%<br/>
<br/>
</td>
<td align="center" valign="top">0.022<br/>
<br/>
</td>
</tr>
<tr>
<td align="left" colspan="6" valign="top">Doubling of Serum Creatinine, ESRD and Death Occurring as a First Event <br/>
</td>
</tr>
<tr>
<td align="left" valign="top">Doubling of Serum <br/>Creatinine <br/>
</td>
<td align="center" valign="top">21.6%<br/>
<br/>
</td>
<td align="center" valign="top">26.0%<br/>
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" valign="top">ESRD <br/>
</td>
<td align="center" valign="top">8.5%<br/>
</td>
<td align="center" valign="top">8.5%<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" valign="top">Death <br/>
</td>
<td align="center" valign="top">13.4%<br/>
</td>
<td align="center" valign="top">12.6%<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" colspan="6" valign="top">Overall Incidence of Doubling of Serum Creatinine, ESRD and Death <br/>
</td>
</tr>
<tr>
<td align="left" valign="top">Doubling of Serum Creatinine <br/>
</td>
<td align="center" valign="top">21.6%<br/>
<br/>
</td>
<td align="center" valign="top">26.0%<br/>
<br/>
</td>
<td align="center" valign="top">25.3%<br/>
<br/>
</td>
<td align="center" valign="top">7.8% to 39.4%<br/>
<br/>
</td>
<td align="center" valign="top">0.006<br/>
<br/>
</td>
</tr>
<tr>
<td align="left" valign="top">ESRD <br/>
</td>
<td align="center" valign="top">19.6%<br/>
</td>
<td align="center" valign="top">25.5%<br/>
</td>
<td align="center" valign="top">28.6%<br/>
</td>
<td align="center" valign="top">11.5% to 42.4%<br/>
</td>
<td align="center" valign="top">0.002<br/>
</td>
</tr>
<tr>
<td align="left" valign="top">Death <br/>
</td>
<td align="center" valign="top">21.0%<br/>
</td>
<td align="center" valign="top">20.3%<br/>
</td>
<td align="center" valign="top">-1.7%<br/>
</td>
<td align="center" valign="top">-26.9% to 18.6%<br/>
</td>
<td align="center" valign="top">0.884<br/>
</td>
</tr>
</tbody>
</table>